Summary
The immunoregulatory activity of ascitic fluids obtained from patients with ovarian carcinoma, and pleural effusions collected from patients with various nonmalignant diseases, was tested. The following assays were performed:in vivo, PFC-response of mouse splenocytes to SRBC;in vitro, antibody-dependent cellular cytotoxicity (ADCC), and phagocytic activity of human peripheral blood mononuclear cells (PBMoC). The migration ability of mouse splenocytes in the presence of ascitic fluids was also evaluated. Parallelly, lipid (triglyceride and cholesterol) and lipoprotein (high-density/HDL/, low-density/LDL/, and very-low-density/VLDL/) content in ascites and pleural effusions, were determined. Both types of fluids suppressed the PFC-response and inhibited phagocytosis of51Cr-labeled sheep erythrocytes by PBMoC, but augmented ADCC of PBMoC against sheep erythrocytes. An elevation of VLDL and a decrease of HDL and LDL in ascitic fluids and pleural effusions, as compared to normal human sera, were found. There were similar changes in the cholesterol content of these lipoprotein fractions, i.e., an increase of VLDL- and a decrease of HDL- and LDL-cholesterol.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- ADCC :
-
antibody-dependent cellular cytotoxicity
- HDL :
-
high-density lipoprotein
- LDL :
-
low-density lipoprotein
- PBMoC :
-
peripheral blood mononuclear cells
- PFC :
-
plaque-forming cells
- SRBC :
-
sheep red blood cells
- VLDL :
-
very low-density lipoprotein
References
Badger AM, Merluzzi VJ, Cooperband SR (1976) Immunostimulatory and immunosuppressive factors in human cancer ascites fluids: Effect on the primary plaque-forming response in vitro. Cell Immunol 27:126–130
Badger AM, Cooperband SR, Merluzzi VJ, Glasgow HA (1977) Immunosuppressive activity of ascitic fluid from patients with cancer metastatic to the peritoneum. Cancer Res 37:1220–1226
Badger AM, Oh SK, Moolten F (1981) Differential effects of an immunosuppressive fraction from ascites fluid from patients with ovarian cancer on spontaneous and antibody-dependent cytotoxicity. Cancer Res 41:1133–1139
Bice DE, Gruwell D, Salvaggio J (1976) Inhibition of macrophage migration by plasma factor (s) from patients with neoplasma and normal individuals. J Reticuloendothel Soc 19:281–289
Boyum A (1968) Separation of leukocytes from blood and bone marrow. Scand J Lab Invest [Suppl 97] 21:77–89
Bradley PW, Blasco PA, Weiss FJ, Alexander CJ, Silverman AN, Chretien BP (1977) Correlation among serum protein-bound carbohydrates, serum glycoproteins, lymphocyte reactivity and tumor burden in cancer patients. Cancer 40:2264–2272
Curtiss JK, DeHeer DH, Edgington TS (1980) Influence of the immunoregulatory serum lipoprotein LDL-In the in vivo proliferation and differentiation of antigen-binding and antibody-secreting lymphocytes during a primary immune response. Cell Immunol 49:1–11
Gabrilovac J, Pachmann K, Thierfelder S (1981) Suppressive activity of cell free ascites obtained from murine tumors. Soluble Fc receptor as a possible active agent. Res Exp Med 178:131–140
Gabrilovac J, Benković B, Burek B, Čepelak I, Boranić M (1982) Immunoregulatory activity of cell-free peritoneal washings of mice with Ehrlich ascitic carcinoma. Res Exp Med 180:147–154
Goren R, Nelken D (1980) Normal immunosuppressive protein. Isolation of a glycoprotein active fraction. Immunology 39:305–309
Hanna N, Ovadia H, Nelken D (1978) Normal immunosuppressive protein: inhibitory effect on immune response against tumour cells. Immunology 34:1007–1015
Hersey P (1973) Macrophage effector function. An in vitro system of assessment. Transplantation 15:282–290
Hršak I, Marotti T (1973) Immunosuppression mediated by Ehrlich ascitic fluid. Eur J Cancer 9:717–724
Hršak I, Marotti T (1974) Mode of immunosuppressive action of Ehrlich ascitic fluid. J Natl Caner Inst 53:1113–1119
Israel L, Edelstein R, Mannoni P, Radot E, Greenspan EM (1977) Plasmapheresis in patients with disseminated cancer: clinical results and correlation with changes in serum protein. Cancer 40:3146–3154
Jerne NK, Nordin NA, Henry O (1963) The agar plaque technique for recognising antibody forming cells. In: Amos B, Koprowski H (eds) Cell bound antibodies. Wistar Institute Press, Philadelphia, pp 109–122
Lowry OH, Rosenbrough MJ, Farra L, Randall RJ (1951) Protein measurement with folin phenol reagent. 193:265–275
Marotti T, Hršak I, Boranić M (1981) Attempt to define immunosuppressive principle (s) in ascites fluid of Ehrlich carcinoma. Period Biol 83:289–294
Marotti T, Hršak I, Krušić J, Deverić G (1982) Immunosuppression related to ascitic fluid in patients with ovarian carcinoma. Oncology 39:298–303
Roth AJ, Grimm AE, Gubta KR, Ames SR (1982) Immunoregulatory factors derived from human tumors. I. Immunologic and biochemical characterization of factors that suppress lymphocyte proliferative and cytotoxic responses in vitro. J Immunol 128:1955–1962
Søberg M, Bendixen B (1967) Human lymphocyte migration as a parameter of hypersensitivity. Acta Med Scand 181:247–256
Takemura-Hattori R, Yamazaki M, Kurisu M, Mizuno D (1980) Depression of macrophage function by lipoprotein from tumorous ascites. Gan 71:206–212
Wieland H, Seidel D (1978) Fortschritte in der Analytik des Lipoproteinmusters. Inn Med 5:290–296
Yi PI, Beck G, Zucker S (1981) Rat plasma lipoprotein inhibitors of lymphocyte proliferation: specific membrane receptor for very low density lipoproteins. Int Arch Allergy Appl Immunol 65:8–14
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marotti, T., Gabrilovac, J., Salzer, B. et al. Immunoregulatory properties and LP-pattern of human ovarian carcinoma ascites and pleural effusions of nonmalignant origin. Res. Exp. Med. 182, 237–244 (1983). https://doi.org/10.1007/BF01851713
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01851713